A Real-Life, Multicenter, Observational Study analyzing Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022
Latest Information Update: 15 Mar 2023
At a glance
- Drugs Adalimumab (Primary) ; Adalimumab (Primary) ; Adalimumab (Primary)
 - Indications Crohn's disease; Ulcerative colitis
 - Focus Adverse reactions; Therapeutic Use
 
Most Recent Events
- 15 Mar 2023 New trial record
 - 01 Mar 2023 Results published in the Inflammatory Bowel Diseases